Cipla Limited has announced that the United States Food and Drug Administration (USFDA) has classified its recent inspection at the company’s manufacturing facility in Virgonagar, Bengaluru, as “Voluntary Action Indicated” (VAI).
This update follows Cipla’s earlier intimation on November 13, 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection conducted at the facility between November 7-13, 2024. The official communication from USFDA was received on February 7, 2025, at 9:03 PM IST.
Cipla Q3 results
On January 28, Cipla Limited announced that it had achieved its highest-ever quarterly revenue of ₹7,073 crore in Q3 FY25, reflecting an impressive 8% year-on-year growth. The company’s EBITDA surged to ₹1,989 crore, marking a 16% increase, with a robust EBITDA margin of 28.1%. Net profit saw an exceptional 50% YoY jump, reaching ₹1,571 crore, with a strong PAT margin of 22.2%.
The growth was fueled by Cipla’s strong performance across key global markets. The India business recorded a 10% YoY increase, driven by branded prescription and trade generics. North America posted quarterly revenue of $226 million, supported by continued momentum in differentiated assets. Emerging markets and Europe experienced an impressive 20% growth in USD terms, while Africa’s prescription business maintained its leading market position with a 9% revenue rise.
Cipla continues to prioritize innovation with R&D investments of ₹360 crore, representing 5.1% of total sales, focusing on product filings and development. The company’s financial position remains solid, boasting a net cash balance of ₹8,947 crore, with debt primarily linked to lease liabilities and working capital needs.
